USANews版 - Merck的新药做过in-patient 的clinical trial, 没有效果之后才开始study out-patient的 |
|---|
|
|
|
|
s****e
发帖数: 720 | 1 看起来确实不是ivermectin, 效果也不如ivermectin。
https://www.wsj.com/articles/pill-intended-to-be-covid-19s-tamiflu-succeeds-
in-key-study-11633082401?mod=searchresults_pos5&page=1
Merck and Ridgeback stopped a study of molnupiravir in hospitalized patients
in April, after researchers found that it failed to help them and is
unlikely to reduce hospital stays and deaths.
The companies continued studying whether the antiviral was effective early
in the course of the disease and in people who are at high risk of Covid-19
complications. Antivirals tend to be most effective when taken soon after
infection and become less beneficial over time as patients get sicker,
according to doctors and scientists.
The Merck-Ridgeback late-stage, or Phase 3, study enrolled more than 1,400
people who were at high risk of becoming seriously ill with Covid-19. To
enroll, participants had to be unvaccinated. About half received an 800-
milligram dose of molnupiravir twice a day for five days, with the other
participants receiving a placebo.
High risk was defined as having at least one characteristic associated with
severe disease or death, such as old age, obesity or diabetes. Treatment
began within five days after the participants developed Covid-19 symptoms. |
|
|
|
|
|
